Here’s What Analysts Are Saying About Teva Pharmaceutical (TEVA) Post Earnings

Core Viewpoint - Teva Pharmaceutical Industries Limited (NYSE:TEVA) is recognized as a strong investment opportunity in the healthcare sector, with recent price target increases from Barclays and Scotiabank following positive fiscal Q4 results [1][2]. Financial Performance - Teva reported three consecutive years of revenue growth, projecting 2025 revenues of $17.3 billion, which represents a 4% year-over-year increase in U.S. dollars and 3% in local currency terms compared to 2024 [3]. - Excluding Japan BV, revenues increased by 5% year-over-year in local currency [3]. - The company's key innovation brands contributed significantly to growth, with projected revenues exceeding $3 billion in 2025, marking a 35% year-over-year increase in local currency [3]. - Fiscal Q4 2025 was notable as it was the first quarter where these innovation brands collectively generated approximately $1 billion in revenues [3]. Analyst Ratings - Barclays maintained an Overweight rating on Teva and raised the price target to $38 from $35, expressing confidence in the stock following the fiscal Q4 report [1]. - Scotiabank also raised its price target to $40 from $35 while maintaining an Outperform rating, citing the company's performance exceeding expectations [2].